PD-1 is named as a drug or biological intervention in 7 clinical trials in our China trial register, 5 of which are recruiting. Lead sponsors include Fudan University (3), Shanghai Jiao Tong University School of Medicine (1) and Suzhou Forlong Biotechnology Co., Ltd (1). Registered phases: Phase 2, Phase 1/2 and Phase EARLY_PHASE1. Conditions studied include Hodgkin Lymphoma; Pancreatic Cancer; Colorectal Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Hodgkin Lymphoma | 1 |
| Pancreatic Cancer | 1 |
| Colorectal Cancer | 1 |
| Colon Cancer | 1 |
| Advanced Solid Tumors | 1 |
| Advanced Solid Tumor | 1 |
| Advanced Hepatocellular Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Fudan University | 3 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Suzhou Forlong Biotechnology Co., Ltd | 1 |
| The Affiliated Hospital Of Guizhou Medical University | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Register | PD-1 trials |
|---|---|
| Clinical trials in China | 7 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PD-1 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PD-1 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.